IPA Total Utang marang Modal ImmunoPrecise Antibodies

Lambang korporat lan logo ImmunoPrecise Antibodies Ltd (IPA)

ImmunoPrecise Antibodies (IPA) generates revenue by providing AI services and contract research for the development of oncology drugs. This chart of the market trend in monetary terms shows a total debt-to-equity ratio of 0.56. ImmunoPrecise Antibodies (IPA) ensures steady B2B demand by offering antibody discovery tools to global pharma behemoths. Risks are minimized through a combination of traditional laboratory analysis and a high-margin IT segment focused on genomic data processing.

ImmunoPrecise (IPA) - Koefisien Total Utang marang Modal saka 04.07.2022 nganti 04.09.2025

Rincian analitis perusahaan ImmunoPrecise Antibodies

- rega lan prakiraan konsensus rega:
Bagan rega ImmunoPrecise Antibodies Ltd|IPA - Prakiraan gabungan firma investasi
- data kapitalisasi pasar:
Kapitalisasi pasar ImmunoPrecise Antibodies|IPA - Nilai Perusahaan
- data kapitalisasi buku:
Nilai Buku saben Saham ImmunoPrecise Antibodies|IPA - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku immunoprecise.com|IPA - Gunggung Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas ImmunoPrecise Antibodies|IPA - Rasio utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas ImmunoPrecise Antibodies Ltd|IPA - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku ImmunoPrecise Antibodies|IPA - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan ImmunoPrecise Antibodies
Ringkesan analisis perusahaan:IPA ImmunoPrecise Antibodies
Produk merek ImmunoPrecise

This ratio determines the proportion of debt capital relative to equity, allowing for an assessment of financial autonomy and bankruptcy risks associated with servicing obligations. By analyzing the company's leverage history, an investor can determine how aggressively ImmunoPrecise Antibodies (IPA) finances the development of its AI platforms for antibody synthesis to maintain technological superiority and patent protection amidst fierce competition.

Pesaing wigati

Utang marang Ekuitas tempus.com (TEM)|Rasio Utang marang Ekuitas Qiagen NV|Total Utang marang Modal IONS|Total Utang marang Modal Repligen Inc. (RGEN)|Total Utang marang Modal RNA|crisprtx.com - Koefisien Total Utang marang Modal|WGS: Utang marang Ekuitas|RARE: Rasio Total Utang marang Ekuitas|BEAM (Beam Therapeutics Corp) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Sarepta Corp|TWST (Twist Bioscience) - Rasio Total Utang marang Ekuitas|Total Utang marang Modal TXG|Utang marang Ekuitas Intellia Therapeutics, Inc. NTLA|Rasio Utang marang Ekuitas STOK (Stoke Therapeutics Inc)|BLFS: Utang marang Ekuitas|Wave Pharma - Utang marang Modal|Utang marang Ekuitas Maze Therapeutics Inc|SION: Utang Agregat marang Ekuitas|Utang marang Ekuitas Prime Medicine PRME|Taysha Gene Therapies Inc (TSHA) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal QURE (uniQure Corp)|Utang marang Modal MeiraGTx Corp|Total Utang marang Modal RGNX (REGENXBIO Inc.)|Rasio Total Utang marang Ekuitas solidbio.com (SLDB)|Total Utang marang Modal OCGN|Pacific Biosciences of California, Inc. - Koefisien Total Utang marang Modal|Utang marang Ekuitas BNTC (Benitec)|DSGN - Koefisien Total Utang marang Modal|Total Utang marang Modal RCKT|Utang marang Modal 4dmoleculartherapeutics.com|LXEO - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi Korro Bio, Inc|Total Utang marang Modal EDIT|Total Utang marang Modal SLN (Silence Therapeutics Corp)|PRQR - Utang marang Ekuitas|CDXS - Rasio Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Sangamo Therapeutics, Inc. SGMO|NAUT - Utang Agregat marang Modal|Metagenomi, Inc - Total Utang marang Modal|Precision BioSciences Inc. (DTIL) - Koefisien Total Utang marang Modal|Total Utang marang Modal Generation Bio Co|Utang marang Ekuitas BOLD|Exicure, Inc. - Utang marang Ekuitas|Utang marang Modal imunon.com (IMNN)|PHIO - Total Utang marang Modal|Rasio Utang marang Ekuitas Mustang Bio Inc MBIO|Total Utang marang Modal RNAZ (TransCode)|BNGO - Koefisien Total Utang marang Modal|Total Utang marang Modal APDN|BLUE (bluebird bio Inc.) - Utang marang Modal|OMGA: Utang marang Ekuitas|Koefisien Total Utang marang Modal Singular Genomics Corp|RGLS (Regulus Therapeutics) - Total Utang marang Modal|Koefisien Total Utang marang Modal SYRS (syros.com)|Telesis Bio (TBIO) - Utang marang Ekuitas|Utang Agregat marang Ekuitas TRACON Pharmaceuticals Inc. TCON|Unity Bio - Total Utang marang Modal